1. Cancer.Net. Lung cancer - non-small cell - statistics. 2012. Accessed June 14, 2023. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
2. Center for Drug Evaluation, Research. FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations. U.S. Food and Drug Administration. Accessed May 17, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr.
3. Molecular pathways and therapeutic targets in lung cancer;Shtivelman;Oncotarget,2014
4. Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada;Kim;Pharmacoeconomics,2021
5. Oncology 2020: a drug development and approval paradigm;Dhingra;Ann Oncol,2015